Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) EBIT Margin (2019 - 2023)

Benitec Biopharma's EBIT Margin history spans 5 years, with the latest figure at 65000.0% for Q2 2023.

  • For Q2 2023, EBIT Margin changed N/A year-over-year to 65000.0%; the TTM value through Mar 2024 reached 307028.57%, down 27869181.0%, while the annual FY2023 figure was 25441.33%, 98380.0% down from the prior year.
  • EBIT Margin for Q2 2023 was 65000.0% at Benitec Biopharma, down from 8038.89% in the prior quarter.
  • Across five years, EBIT Margin topped out at 7056.1% in Q2 2020 and bottomed at 379300.0% in Q1 2021.
  • The 5-year median for EBIT Margin is 8038.89% (2023), against an average of 80711.97%.
  • The largest annual shift saw EBIT Margin crashed -37176071bps in 2021 before it skyrocketed 37209375bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 2741.56% in 2019, then tumbled by -11787bps to 325900.0% in 2020, then skyrocketed by 94bps to 19340.0% in 2021, then plummeted by -107bps to 40071.43% in 2022, then plummeted by -62bps to 65000.0% in 2023.
  • Per Business Quant, the three most recent readings for BNTC's EBIT Margin are 65000.0% (Q2 2023), 8038.89% (Q1 2023), and 40071.43% (Q4 2022).